Recent Quotes
My Watchlist
Indicators
Star 60
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

23.26 +0.56 (+2.47%)
Streaming Delayed Price Updated: 12:09 PM EST, Jan 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Catalyst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
2 Incredible Growth Stocks to Buy Hand Over Fist Right Now ↗
These two healthcare stocks may be deeply undervalued. 
Via The Motley Fool
News headline image
Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating ↗
On Tuesday, Catalyst Pharmaceuticals stock hit a key technical milestone, with its Relative Strength Rating climbing to 83 from 79. 
Via Investor's Business Daily
News headline image
Decoding 8 Analyst Evaluations For Catalyst Pharmaceuticals ↗
 
Via Benzinga
News headline image
Catalyst's New CEO Has Big Ideas For The Small Biotech ↗
Richard Daly is Catalyst Pharmaceuticals' second CEO, taking over for Patrick McEnany, who retired last year. 
Via Investor's Business Daily
News headline image
Decoding 7 Analyst Evaluations For Catalyst Pharmaceuticals ↗
 
Via Benzinga
News headline image
Assessing Catalyst Pharmaceuticals: Insights From 4 Financial Analysts ↗
 
Via Benzinga
News headline image
Earnings Preview For Catalyst Pharmaceuticals ↗
 
Via Benzinga
News headline image
CPRX Stock Earnings: Catalyst Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 ↗
CPRX stock results show that Catalyst Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Top 10% Biotech Catalyst Pharma Slips On Mixed First-Quarter ↗
The company doubled Wall Street's earnings views, but sales came in short. 
Via Investor's Business Daily
News headline image
Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
The Company will Host a Conference Call and Webcast on Thursday, May 9, 2024, at 8:30 AM ET 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List ↗
Don’t miss out on these three strong buy biotech stocks that are leaders to add to your portfolio for Q2 this year. 
Via InvestorPlace
News headline image
7 Biotech Stocks Ready to Ride the Sector’s Resurgence ↗
With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas. 
Via InvestorPlace
News headline image
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark ↗
On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago. 
Via Investor's Business Daily
News headline image
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
3 Sexy Small-Cap Stocks to Add Sizzle to Your Portfolio ↗
While small-cap stocks can be incredibly risky, they also offer the potential for dramatic gains you won’t find with the big dogs. 
Via InvestorPlace
News headline image
Amicus Therapeutics Stock Sees RS Rating Improve To 74 ↗
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday. 
Via Investor's Business Daily
News headline image
3 Biopharma Stocks You Don't Want to Miss in the New Bull Market ↗
All three have exciting programs on the way. 
Via The Motley Fool
News headline image
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Top 3 Health Care Stocks You May Want To Dump In Q1 ↗
As of Feb. 29, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. 
Via Benzinga
News headline image
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology
Santhera's Study Reports the Results of the 48-Week Treatment with Vamorolone in Patients with Duchenne Muscular Dystrophy (DMD) in the VISION-DMD Study, Supporting the Long-Term Efficacy and Safety... 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
The Company will Host a Conference Call and Webcast on February 29, 2024, at 8:30 AM ET 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Jim Cramer Likes This Bank 'Very, Very Much,' Says Stock Is Up 7% Over Past 6 Months ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Stanley Black & Decker, Inc. 
Via Benzinga
News headline image
Next Big Thing: 3  Biotech Stocks to Watch for Groundbreaking Advances ↗
With our improving economy, you need to invest in these top biotech stocks that are looking to strike gold this year. 
Via InvestorPlace
Topics Economy
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.